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Background: Central nervous system involvement in myotonic dystrophy type 1
(DM1) is associated with cognitive deficits, impaired social performance and excessive
somnolence, which greatly impact quality of life. With the advent of clinical trials
in DM1, there is a pressing need to identify outcome measures for quantification of
central symptoms that are feasible and valid. In this context, we sought to evaluate
neuropsychological and self-reported measures currently recommended by expert
consensus, with particular reference to their specificity for central nervous system
involvement in a moderate-sized DM1 cohort.
Methods: Forty-five adults with DM1 and 20 controls completed neuropsychology
assessments and symptom questionnaires. Those without contraindication also
underwent MRI brain, from which global gray matter volume and white matter lesion
volume were quantified. CTG repeat was measured by small pool PCR, and was
screened for the presence of variant repeat sequences.
Results: The neuropsychology test battery was well tolerated and detected
impairment across various domains in the DM1 group vs. controls. Large effect sizes
in the Stroop and Trail Making Tests were however attenuated by correction for
basic speed, which could be influenced by dysarthria and upper limb weakness,
respectively. Low mood was strongly associated with increased self-reporting of
central symptoms, including cognitive impairment. Conversely, self-reported cognitive
impairment did not generally predict poorer performance in neuropsychology
assessments, and there was a trend toward greater self-reporting of low mood and
cognitive problems in those with milder white matter change on MRI. Global gray
matter volume correlated with performance in several neuropsychology assessments
in a multivariate model with age and sex, while white matter lesion volume
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was associated with executive dysfunction reported by a proxy. Screening for variant
repeats was positive in three individuals, who reported mild muscle symptoms.
Conclusions: Identification of outcome measures with good specificity for brain
involvement in DM1 is challenging, since complex cognitive assessments may be
compromised by peripheral muscle weakness and self-reported questionnaires may be
influenced by mood and insight. This highlights the need for further large, longitudinal
studies to identify and validate objective measures, which may include imaging
biomarkers and cognitive measures not influenced by motor speed.
Keywords: myotonic dystrophy, neuropsychology assessment, outcome measures, small pool PCR, voxel based
morphometry
INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a dominantly inherited,
multisystem condition (1) resulting from the abnormal
expansion of a CTG trinucleotide repeat (2). The clinical
phenotype is highly variable, with larger CTG repeats broadly
associated with earlier onset and more severe symptoms (3).
Although the phenotype presents as a clinical continuum, DM1
may be sub-categorized according to age at onset of symptoms
from congenital-onset, through infantile-onset (childhood
before age 10 years), juvenile-onset (childhood after 10 years), to
adult- and late-onset forms (4).
Symptoms arising from central nervous system (CNS)
involvement in DM1 are common (5), and vary in their
impact across this clinical spectrum. In congenital-onset
DM1, intellectual disability is a consistent finding, and is
frequently accompanied by additional neurodevelopmental
diagnoses including autism spectrum disorders (6–8). In
infantile- and juvenile-onset forms, learning difficulties are often
present, but are typically milder than those seen in congenital-
onset DM1 (9). Educational attainment in these groups may
however be further compromised by concomitant attention
deficit, autism spectrum or anxiety disorders (7, 10, 11).
The CNS phenotype in adult-onset DM1 is characterized by
more subtle deficits of cognition. In this group, global cognitive
function is usually found to be normal when measured by
standard tools such as the Mini Mental State Examination
(12–14), although distribution may be shifted toward the lower
end of the general population range. Case-control studies
however have demonstrated impaired performance in a range
of targeted neuropsychological assessments, consistent with
deficits of visual perception and construction, social cognition,
psychomotor speed, executive functioning, visual memory and
attention, with smaller effect sizes observed in language and
verbal memory domains [reviewed in (15)]. Deficits are typically
present in several domains in an affected individual (16), and
longitudinal studies confirm progression of cognitive symptoms
with time (17–19).
Changes in personality are also described in DM1. Distinctive
traits include a tendency toward apathy, and avoidant behaviors
such as reluctance to seek new experiences, make new friends
or form intimate relationships (20–22). Furthermore, excessive
daytime somnolence is commonly reported, and may occur in
the absence of sleep disordered breathing (23), suggesting a
central contribution to this symptom. Imaging studies confirm
structural brain changes in DM1, characterized onMRI scanning
by progressive, widespread atrophy and the presence of white
matter lesions (24–26). Further, diffusion tensor imaging (DTI)
reveals the presence of diffuse, microstructural disruption even
in apparently normal-looking white matter (27). Correlations
have been described between impairment in specific cognitive
domains or CTG repeat length with measures of gray matter
volume (28–31), total volume of white matter lesions (VWML)
(31–34) and DTI measures (29, 31–36), although findings
are inconsistent between studies, and no consensus imaging
biomarker for CNS involvement has yet been identified (37).
Together, cognitive difficulties, loss of drive, and excessive
sleepiness conspire with physical impairments to greatly impact
individuals’ quality of life, affecting participation in activities
related to family life, leisure, employment and self-management
of healthcare (38).
Recent trials involving human participants of potential
disease-modifying therapies for DM1, including antisense
oligonucleotide and the GSK3β inhibitor tideglusib, emphasize
clinical trial readiness as a major priority for the DM1 research
community (39). With respect to CNS symptoms, the Outcome
Measures in Myotonic Dystrophy (OMMYD) working group
(40, 41), and DM CNS taskforce (42), have highlighted the
need for a validated, consensus approach to the measurement
of central symptoms in the context of clinical trials. Criteria for
endorsement of outcome measures by the OMMYD group are
based on the OMERACT (Outcome Measures in Rheumatology)
filter, a process first devised for selection of clinical trial outcome
measures for rheumatological disorders (43). The OMERACT
filter requires that a measure is truthful (i.e., measures the aspect
of disease that is intended), discriminates between situations
of interest (for example for classification of disease states, or
is sensitive to change over time), and is feasible within the
constraints of the intended study.
Regarding outcome measures for CNS involvement in DM1,
OMMYD has recommended four neuropsychology assessments,
based on evidence from previous case control studies: the
Stroop test (12, 20, 44–46), Block Design subtest from Weschler
Adult Intelligence Scale-Revised (WAIS-R) (12, 44, 46, 47), FAS
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controlled oral word association (12, 44, 47), and Trail Making
Tests A and B (12, 20, 44, 47). In addition, several self-reported
symptom questionnaires have been specifically developed for use
in DM1, including DM1-ActivC© (48), a measure of physical
ability to complete activities of daily living, and the fatigue and
daytime sleepiness scale (FDSS) (49). The Myotonic Dystrophy
Health Index (MDHI) (50) allows self-rating of symptoms across
a range of domains, including fatigue, cognition and social
performance.
While existing data support the sensitivity of these tools to
impairment in DM1, and their feasibility in the context of clinical
research, no study to our knowledge has explored their specificity
for brain involvement in DM1 (their “truthfulness” with respect
to the OMERACT filter). We hypothesized that performance
in complex neuropsychology assessments rewarding rapid
completion of a manual task, such as the Trail Making test
and Block Design tests, or rewarding rapid speech, such as
the Stroop test, may be compromised by a more basic speed
limitation that could in turn be influenced by peripheral muscle
weakness in DM1. Further, we hypothesized that the impairment
of insight described as part of the DM1 phenotype (51) may
be particularly marked with respect to deficits of cognition and
social functioning, undermining the validity of self-reporting
scales for measurement of CNS disease if used in isolation.
In this context, we designed a study protocol including
neuropsychology tests and self-reported symptom questionnaires
recommended by OMMYD, with the aim of evaluating their
suitability for use as CNS outcome measures. A correction step
was applied to the Stroop, Trail Making and Block Design tests
to quantify the relative contributions of basic speed limitation
and higher cognitive deficits to performance in these tests. Self-
reported symptoms and neuropsychology data were compared
with objective measures of global CNS disease burden, measured
on MRI imaging.
Correlations of outcome measure scores with CTG repeat
lengths were also explored. To address the limitation of
traditionally used molecular methods, that fail to take account
of age-dependent somatic mosaicism of the expanded allele (52),
a small-pool PCR (SP-PCR) approach was used for genotyping,
that has been shown to improve correlations with age at onset
of symptoms (53). In addition, since the presence of sequence
interruptions (variant repeats) within the CTG repeat array,
present in in around 3 to 5% of individuals with DM1, has
been linked to unusually mild or atypical symptoms (54), all
participants were also screened for the presence of variant
repeats.
METHODS
Recruitment and Administration
Patients with DM1 attending annual review appointments at the
West of Scotland Clinical Genetics Service were contacted by
letter and invited to participate. Recruitment was restricted to
those with adult or late onset DM1; a clear onset of DM1-specific
symptoms before age 16 years or learning disability diagnosed
in childhood were criteria for exclusion. Controls were recruited
either from families of DM1-affected participants, or via the
Scottish Health Research Register (SHARE) (55). Participants
from both groups were excluded if they had a history of severe
head injury, or a neurological disorder other than DM1.
Written informed consent was obtained from all participants,
and the study has undergone ethical review (West of Scotland
Research Ethics Committee; 15/WS/0189). DM1-affected
subjects could choose between completing neuropsychology
assessments and questionnaires in a hospital clinic room or
in their own home. Control participants were assessed in a
hospital clinic room. All neuropsychology assessments and
questionnaires were administered by a single operator (MJH),
following training by a Professor of Applied Neuropsychology
(JJE).
Neuropsychology Tools
The neuropsychology test battery included a commercial version
of the Stroop test (Golden and Freshwater© Stoelting Co. 2002),
Trail Making Tests from the Delis-Kaplan Executive Function
System (D-KEFSTM) and the Block Design test from Weschler
Abbreviated Scale of Intelligence (WASI-II). These assessments
were applied and scored according to the authors’ instructions.
Participants also completed the Edinburgh Cognitive and
Behavioral ALS Screen (ECAS) (56). ECAS was devised for use
in amyotrophic lateral sclerosis, but includes cognitive domains
relevant to DM1, has medium to high concurrent validity with
standard tools (57) and, crucially, does not include any tasks that
require manual dexterity. Finally, participants completed an FAS
controlled oral word association test. Since the ECAS includes a
controlled word association test for the letter “S,” two additional
conditions were applied for each subject, using the letter “F,” then
“A.”
Corrections for Basic Speed
Participants completed three conditions of the Stroop test; a
word card, a color card, and finally a color-word card. To
control for basic reading speed, a predicted score for the color-
word task was calculated from the raw word and color scores,
using the nomogram in the test manual (58). The difference
between the predicted and actual performance in color-word
constituted the Interference score. In the D-KEFS Trail Making
Tests, performance in the number-letter switching trail (Trail 4)
was corrected by comparison to performance in Trail 5, which
involved tracing a pre-defined trail marked by a dotted line.
Performance in Trail 5 subtracted from Trail 4 constituted the
Motor Contrast Score. In the WASI-II Block Design subtest, the
authors’ instructions advise graded scoring, with more points
awarded for completion of designs within a shorter time. Scores
calculated in line with the authors’ instructions were recorded as
the “standard score.” To eliminate weighting for speed, the raw
number of designs correctly completed by each participant was
also recorded as the “non-adjusted score.”
Comparison of ECAS With Other Cognitive
Tests
The total score for ECAS may be sub-divided into language,
verbal fluency, executive, memory and visuospatial domain
subscores. Performance in four tasks contributes to the
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executive subdomain score; a reverse digit span, a number-
letter alternation task, a social cognition test, and a sentence
completion task to assess cognitive inhibition (56, 59). To further
explore the validity of OMMYD-recommended tools, selected
components were compared with the score or scores from
ECAS intended to assess comparable cognitive domains. The
Stroop color-word and interference scores were compared with
the ECAS total executive subscore, and score for the cognitive
inhibition task alone. The number-letter switching and motor
contrast Trail Making scores were compared with the ECAS
total executive subscore and number-letter alternation task alone.
Block design scores were compared with the ECAS visuospatial
and executive subscores. FAS oral word association score was not
compared with the ECAS verbal fluency score, since both utilized
the same controlled oral word association format.
Self- and Informant-Reported Outcomes
All participants completed Fatigue and Daytime Sleepiness Scale
(FDSS) (49), Beck Depression Inventory II (BDI II) (60), visual
analog scale from the Short-form McGill Pain Questionnaire
(61), bodily pain items from Short Form-36 (SF-36) (62), and the
Dysexecutive questionnaire from the Behavioral Assessment of
the Dysexecutive Syndrome (self-DEX) (63).
DM1-affected participants additionally completed The MDHI
(50), DM1-ActivC © (48), and were asked to nominate a close
relative, friend or carer to complete a Dysexecutive questionnaire
(informant-DEX).
Measurement of CTG Repeat Expansion
Genotyping of the CTG trinucleotide repeat in DM1 participants
was completed by SP-PCR as previously described (52). Four
reactions, each using 300 pg blood genomic DNA template, were
performed for each patient. CTG repeat lengths were estimated
by comparison against DNA fragments of known length in the
molecular weight marker. The lower boundary of the expanded
molecules in SP-PCR was used to estimate the inherited, or
“progenitor” allele length (ePAL), (52) which is the major
determinant of age at onset of symptoms (53), while the region of
greatest band intensity constitutes the modal allele length (MAL)
at the time of sampling. Samples were also screened for presence
of variant repeats within the CTG repeat array by exposure to
AciI enzyme (64).
MRI
Participants attended a singleMRI session at the GlasgowClinical
Research Facility at the Queen Elizabeth University Hospital,
Glasgow. Provision of transport by taxi free of charge, or
reimbursements of reasonable travel expenses were offered to all
participants. Height and weight were recorded prior to scanning.
Imaging was undertaken using a 3T Siemens Prisma MRI
scanner (Software version: VE11B. Erlangen, Germany), with
a 20 channel head and neck receiver coil. Pertinent sequences
for the analysis presented here were T1-w 3D MPRAGE (TR =
2,300ms, TE = 2ms, TI = 900ms, flip = 10◦) and T2-w SPACE
dark fluid (TR = 5,000, TE = 386ms, TI = 1800ms, flip =
120◦). The whole brain was imaged, both sequences had 1.1mm
× 1.1mm× 1.1mm voxels.
T1-w 3D MPRAGE and the T2-w SPACE dark fluid
sequences were analyzed using a Lesion Growth Algorithm
(LGA) (http://www.applied-statistics.de/lst.html) (65), from the
Lesion Segmentation Toolbox (LST). The LGA creates a lesion
probability map, from which the number of and total volume of
white matter hyperintensities were derived.
Prior to determining major brain tissue class volumes, the
T1-w 3D MPRAGE images were lesion-filled using the LST
toolbox. This sought to minimize the percentage error in the
tissue segmentation process due to the white matter lesions
(66). Following this the filled images were then segmented (67)
using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/). Gray matter
volume, white matter volume and cerebrospinal fluid volume
were obtained. Gray matter and white matter volumes were
expressed as a percentage of total intracranial volume for further
analysis (GMV andWMV, respectively).
Statistical Analysis
Block Design standard score and all Stroop test subscores
were converted to age-adjusted T-scores using normative data
provided in the test manual. D-KEFS Trail Making scores were
likewise converted to age-adjusted scaled scores using the test
manual. Progenitor allele length (ePAL) was converted to a
logarithm with base 10 (logPAL) for statistical analysis to achieve
a normal distribution. Comparison of means was undertaken
using Statistical Package for the Social Sciences (SPSS, Version
24.0; IBM 2015), Cohen’s effect size was calculated using
G∗Power (version 3.1) (68) and linear regression analysis carried
out using R statistics software (version 3.3.2; www.r-project.org).
To address the issue of multiple comparisons, the Benjamini-
Hochberg correction was applied to all linear regressions,
using an on-line tool (Macdonald JH, 2014; http://www.
biostathandbook.com/multiplecomparisons.html) with a false
discovery rate of 0.05. All linear regression analyses and
Benjamini-Hochberg correction are demonstrated in on-line
Supplementary File S2.
RESULTS
Raw results data are provided in on-line Supplementary File S1.
Cohort
Forty-seven individuals were recruited from theWest of Scotland
service. One participant was withdrawn due to an unexpected
finding of a possible glial neoplasm on MRI brain. Another
subject with a historical genetic diagnosis of DM1 was found to
have an expanded allele of 43 repeats only on re-testing. DM1-
specific features were absent on clinical evaluation, and so her
diagnosis of DM1 was revised to that of a premutation carrier.
This subject was excluded from the main analysis, although
her data were included in linear regression analysis of imaging
findings with CTG repeat length. Six subjects completed the
protocol excluding MRI due to contraindications (three with
permanent pacemaker, two claustrophobia and one high body
mass index). Forty-five DM1-affected participants, 39 with MRI
data, were therefore included in the main analysis. Twenty
control subjects were also recruited; 12 from patients’ families,
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and eight from SHARE. Comparison of clinical characteristics are
summarized in Table 1. Four DM1 participants were prescribed
modafinil, and none mexiletine. No participants had diabetes
mellitus. In both control and DM1-affected cohorts, mean age of
male, and female participants was not significantly different in
independent samples t-test.
Tolerability of the Protocol
Stroop data were incomplete for four DM1-affected participants;
one because the tool was not available, one male could not
complete the color tasks due to red-green color blindness,
and a third became frustrated and disengaged during the
color-word task. Data from the fourth was excluded as she
had a diagnosis of visual stress (Mears-Irlen syndrome), and
obtained exceptionally low scores in Stroop despite above-
average performance in other cognitive domains. Two DM1-
affected participants declined to answer items within MDHI,
as they felt these were offensive or intrusive (questions related
to personality and sexual function, respectively). One DM1-
affected participant declined to nominate a relative to complete
the informant-DEX questionnaire, and another was unable to
identify a suitable contact due to social isolation. All participants
who commenced MRI scanning were able to tolerate the full
imaging protocol.
Deficits in the DM1-Affected Group
Compared With Controls
Comparison of neuropsychology scores from DM1-affected
participants with control participants are summarized in
Table 2A. The DM1-affected group had lower scores on
average in all elements of the Stroop, D-KEFSTM Trail Making,
Block Design and FAS oral word association tests. The mean
total score for ECAS was also lower in the DM1-affected
group (p = 0.004), though subscores for verbal fluency and
memory only approached statistical significance (p = 0.112,
0.085). Visuospatial and language subscores of ECAS showed a
significant ceiling effect in DM1-affected participants, with 24
TABLE 1 | Demographic details of DM1-affected and control cohorts.
DM1-affected Control p
Number 45 20 –
Female: number (%) 26 (58%) 8 (40%) 0.282
†
Age: mean (SD) 46.87 (12.37) 46.06 (13.14) 0.754*
Years of education: mean (SD) 14.38 (2.83) 14.48 (3.19) 0.971*
Smoking status
Never: Former: Current (ratio)
27: 7: 11 5: 14: 1 <0.001
†
Muscle impairment rating scale
(MIRS)
1:2:3:4:5 (ratio)
3: 7: 10: 23: 2 – –
ePAL: mean number of CTG
repeats (SD)
235 (121) – –
MAL: mean number of CTG
repeats (SD)
479 (253) – –
*Independent samples t-test;
†
Chi-square test.
(53%) and 15 (33%), respectively gaining the maximum possible
score in these subsections (Supplementary File S1).
Correction of performance in the Stroop color-word test for
basic reading speed attenuated the Cohen’s d effect size from a
large 1.266 to a smaller, though still significant 0.619 compared
with controls. Performance on the D-KEFSTM Trail Making
number-letter switching task was no longer significantly different
after controlling for basic motor speed (Motor contrast score; p=
0.221). In the Block Design subtest, the large effect size remained
when weighting for speed was eliminated (standard score vs.
non-adjusted score, Cohen’s d = 1.592 vs. 1.459, respectively).
DM1-affected participants reported greater fatigue, lower
mood and greater pain on FDSS, BDI II, and McGill visual
analog scales, respectively (Table 2B). There was a trend toward
greater everyday executive dysfunction as measured by the self-
DEX questionnaire, and greater pain reported by SF-36, though
these differences did not reach statistical significance (p =
0.102, 0.061). Levels of low mood, fatigue and pain that could
be considered clinically significant were reported frequently in
DM1-affected participants. Thirteen (29%) had a BDI II score
greater than 13, 27 (60%) had an FDSS score greater than two
SDs above the mean score of controls, and 16 (36%) rated bodily
pain as “moderate” or greater on SF-36.
Comparison of ECAS With Other Cognitive
Assessments
Performance in the Stroop color-word task did not significantly
correlate with ECAS total executive subscore, or score in the
sentence completion/cognitive inhibition task alone. The same
was true for Stroop Interference score. Performance in the D-
KEFSTM number-letter switching trail did not correlate with the
number-letter alternation task of ECAS alone, but had a relatively
weak positive correlation with total ECAS executive subscore (p
= 0.006, Adj R2 = 0.141). The D-KEFSTM motor contrast score
did not correlate with the ECAS number-letter alternation task
or the total executive subscore.
Block Design standard score was positively correlated with
both the ECAS visuospatial subscore (p = 0.008, Adj R2 =
0.134) and the ECAS executive subscore (p = 0.011, Adj R2 =
0.122). Similarly, the Block Design non-adjusted score correlated
weakly with the ECAS visuospatial subscore (p = 0.024, Adj R2
= 0.092) and with the executive subscore (p = 0.009, Adj R2 =
0.127). Only the relationship between the Block Design standard
score and ECAS visuospatial subscore remained significant after
Benjamini-Hochberg correction. Of note, correlations with the
ECAS visuospatial score were likely hampered by the ceiling
effect previously described, in that 53% of DM1-affected subjects
gained the maximum possible points for this subsection.
Relationships Between Self-reported
Symptoms
In the DM1-affected group, significant co-linearity was observed
between self-reported scales of fatigue, pain and low mood. BDI
II score correlated positively with FDSS score (p < 0.001, Adj R2
= 0.394; Figure 1A), and with McGill pain scale (p < 0.001, Adj
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TABLE 2A | Comparison between DM1-affected participants and controls in neuropsychology assessments.
Affected n. Control n. DM1-affected
participants: Mean (SD)
Control participants:
Mean (SD)
Effect size
(Cohen’s d)
P
STROOP TEST (T-SCORE)
Word task 43 20 39.42 (11.39) 48.95 (6.67) 1.021 <0.001
Color task 42 20 36.71 (10.87) 49.30 (7.23) 1.364 <0.001
Color-word task 41 20 41.95 (10.56) 53.80 (7.98) 1.266 <0.001*
Interference 41 20 47.34 (6.88) 51.60 (6.88) 0.619 0.022*
D-KEFSTM TRAIL MAKING (SCALED SCORE)
1. Number scanning 45 20 9.00 (2.71) 11.50 (2.12) 1.028 0.001
2. Number sequencing 45 20 7.84 (3.77) 12.00 (1.59) 1.438 <0.001*
3. Letter sequencing 45 20 8.27 (3.86) 12.50 (2.04) 1.370 <0.001*
4. Number-letter sequencing 45 20 8.42 (4.25) 11.70 (2.00) 0.988 0.001*
5. Motor 45 20 8.96 (3.32) 12.55 (1.32) 1.421 <0.001*
Motor contrast score 45 20 9.51 (3.74) 9.15 (2.48) 0.113 0.221*
FAS WORD ASSOCIATION
Number of words 45 20 37.00 (10.92) 47.10 (11.11) 0.917 0.001
WASI-II BLOCK DESIGN
Standard score (T-score) 45 20 37.49 (9.88) 52.15 (8.49) 1.592 <0.001
Non-adjusted score 45 20 7.58 (2.73) 10.75 (1.41) 1.459 <0.001
ECAS
Language 45 20 26.58 (1.94) 27.20 (2.07) 0.309 0.012*
Verbal fluency 45 20 17.51 (3.60) 18.70 (3.91) 0.317 0.112*
Executive 45 20 35.80 (6.17) 39.35 (5.80) 0.593 0.013*
Memory 45 20 17.04 (3.81) 18.90 (2.83) 0.554 0.085*
Visuospatial 45 20 11.13 (1.25) 11.85 (0.37) 0.781 0.010*
Total score 45 20 108.07 (11.74) 116.00 (9.50) 0.743 0.004*
TABLE 2B | Summary of self-reported symptom scores of DM1-affected participants and controls.
Affected N Control N DM1-affected
participants: Mean (SD)
Control participants:
Mean (SD)
Effect size
(Cohen’s D)
p
Self-DEX 45 20 17.89 (11.60) 12.70 (8.05) 0.520 0.102* ↑
BDI II 45 20 11.22 (8.76) 5.05 (5.09) 0.858 0.001* ↑
FDSS Centile Score 45 20 37.47 (15.59) 17.00 (9.03) 1.607 <0.001* ↑
SF-36 Pain Items 45 20 4.76 (2.48) 3.45 (1.61) 0.627 0.061* ↑
McGill Pain Scale 45 20 22.18 (24.03) 9.20 (13.73) 0.663 0.046* ↑
DM1-ActivC© centile 45 – 69.78 (20.00) – – – ↓
MDHI total 45 – 27.78 (21.66) – – – ↑
Comparison of means was carried out as an independent samples t-test if data were normally distributed in both groups (defined as p > 0.05 in Shapiro Wilk test of normality). If data
were not normally distributed in one or both groups, a non-parametric Mann Whitney U-test was applied. P-values that relate to a non-parametric test are marked *.
BDI II, Beck Depression Inventory II; D-KEFSTM, Delis Kaplan Executive Frontal System; ECAS, Edinburgh Cognitive and Behavioral ALS screen; FDSS, Fatigue and Daytime Sleepiness
Scale; MDHI, Myotonic dystrophy health index; WASI-II, Weschler Abbreviated Scale of Intelligence. Direction of the arrows indicates the trend that is associated with more severe
symptoms.
R2 = 0.255). In turn, FDSS also correlated with McGill pain scale
(p < 0.001, Adj R2 = 0.321).
A highly significant relationship was also observed between
mood (BDI II score) and self-reported CNS symptoms. Patients
with more symptoms of depression tended to report more
cognitive problems (MHDI cognitive impairment subscale; p <
0.001, Adj R2 = 0.626), everyday executive difficulties (self-DEX;
p < 0.001, Adj R2 = 0.480) and impaired social performance
(MDHI social performance subscale; p < 0.001, Adj R2 = 0.441;
Figures 1B–D). Subjects’ rating of their own everyday executive
dysfunction (self-DEX) correlated significantly, but weakly with
the same scale completed by a proxy (informant-DEX; p= 0.006,
Adj R2 = 0.147).
Comparison of MDHI subscores with other self-rating scales
for similar themes showed good correlations. Mobility (p <
0.001, Adj R2 = 0.746), upper extremity function (p < 0.001,
Adj R2 = 0.531) and ability to do activities (p < 0.001, Adj R2
= 0.684) subscales all correlated inversely with DM1ActivC©
score as expected. BDI II score correlated with the emotional
issues subscale (p < 0.001, Adj R2 = 0.611), FDSS centile score
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FIGURE 1 | Beck Depression Inventory II score was positively correlated with (A) Fatigue Daytime Sleepiness Scale centile score; (B) MDHI cognitive impairment
subscore; (C) self-dysexecutive (DEX) score; and (D) MDHI social performance subscale.
correlated with the fatigue subscale (p < 0.001, Adj R2 = 0.504),
and both SF-36 pain items and McGill pain scale correlated well
with MDHI pain subscale scores (p < 0.001, Adj R2 = 0.524, and
Adj R2 = 0.582, respectively).
Self-reported Symptoms and Cognitive
Performance
Self-DEX, BDI-II, FDSS and McGill pain scores alone did
not correlate with performance in any of the neuropsychology
assessments. The cognitive impairment subscore of MDHI was
inversely correlated with Stroop Interference score only (p =
0.009, Adj R2 = 0.142).
Greater physical impairment measured by DM1ActivC© was
significantly associated with poorer performance in the visual
scanning (p= 0.001, Adj R2 = 0.198) and motor task (p < 0.001,
Adj R2 = 0.305) of the D-KEFSTM Trail Making Tests, as well
as total standard score (p < 0.001, Adj R2 = 0.229) and non-
adjusted score (p < 0.001, Adj R2 = 0.210) of the Block Design
subtest. Executive impairment rated by a proxy (Informant-DEX)
showed an inverse correlation with Stroop word task score only
(p= 0.003, Adj R2 = 0.181).
Genotype-Phenotype Correlations
In univariate analysis, logPAL did not correlate with performance
in any of the neuropsychology assessments, nor with any self-
reported symptoms. Since logPAL represents an estimation of
CTG repeat size at conception, its influence on phenotype
would be expected to be age-dependent. Hence we also explored
correlations with logPAL in a multivariate model [age + logPAL
+ (age∗logPAL)], demonstrating a significant correlation with
the MDHI mobility subscale (p = 0.008, Adj R2 = 0.194) and
block design non-adjusted score (p= 0.005, AdjR2= 0.212) only.
Increasing MAL significantly correlated with greater physical
impairment measured by MDHI mobility subscale (p = 0.001,
Adj R2 = 0.211) and DM1-ActivC© score (p = 0.006, Adj R2
= 0.143), as well as poorer performance in the Block Design
standard score (p= 0.003, Adj R2 = 0.168).
AciI enzyme digest identified three individuals as carrying
variant trinucleotide repeats; a 22 year old female, 33 year old
male, and a 36 year oldmale. Their neuropsychology and imaging
data were not remarkably different to other DM1-affected
individuals of similar age (online Supplementary File S1).
However all reported minimal physical impairment due to their
DM1 symptoms (DM1ActivC© centile score 100, 88, and 93),
despite an ePAL of 251, 217, and 158 repeats, respectively.
MRI
Mean GMV was lower in the DM1-affected participants
compared with controls as expected (46.5 vs. 51.0%; p = 0.003).
Within the DM1 cohort only, mean GMV was also significantly
lower in males compared with females (44.2 vs. 48.4%; p =
0.023; Figure 2), despite sexes being well matched for age, and
mean ePAL being significantly higher in females who underwent
imaging (265 vs. 171 repeats; p = 0.004). A possible sex effect
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FIGURE 2 | Gray matter volume, expressed as percentage of total intracranial
volume, plotted against age. Trend lines demonstrate an apparent sex effect
that was exaggerated in DM1-affected participants.
TABLE 3 | Significance level of predictor variables in multiple linear regression
model GMV ∼ age + sex + logPAL, using data from 39 DM1-affected individuals
and one premutation carrier.
Variable Standardized beta coefficient p
Age (years) −0.815 <0.001
Sex (male = 0; female = 1) 0.322 0.002
logPAL −0.245 0.018
in the DM1 group was further evidenced by improvement of the
inverse correlation between GMV and age (Adj R2 = 0.622) by
inclusion of both age and sex in a multivariate model (Adj R2 =
0.665). The model improved further with inclusion of age, sex
and logPAL (n. = 40 including subject with premutation; Adj R2
= 0.697; Table 3).
Gray matter volume alone did not significantly correlate
with performance in neuropsychology assessments, except
the Stroop word and color tasks. Given the observed
sex differences in GMV, and that our cohort was highly
heterogeneous in age, we repeated linear regression analyses
including sex and age as covariates, which improved
correlations with several measures, although most were
non-significant after correction for multiple comparisons
(Table 4).
To further explore the relative effect of GMV and muscle
impairment on cognitive performance, while controlling for
other factors, DM1-ActivC© score was then added to this
multivariate model, to give: score ∼ age + sex + GMV + DM1-
ActivC© (Table 5). Addition of DM1-ActivC© improved the fit
of the model, reflected by an increase in Adj R2, for the Stroop
color and word tasks, Trails 1–5 of the D-KEFS Trail Making
Tests and both the Block Design standard and non-adjusted
scores. The contribution of DM1-ActivC© score to the model
reached statistical significance (at p < 0.05 without correction
TABLE 4 | Linear regression analysis between GMV and neuropsychology
assessment scores in DM1-affected participants only, demonstrating
improvement with multivariate models including sex and age.
Age
Adj R2
GMV
Adj R2
GMV + sex
Adj R2
GMV + sex + age
STROOP TEST (T-SCORE)
Word task ns 0.171 0.200 p = 0.003
Adj R2 = 0.280
Color task ns 0.316 0.367 p < 0.001
Adj R2 = 0.399
Color-word task ns (0.101) 0.287 p < 0.001
Adj R2 = 0.353
Interference ns ns 0.275 p = 0.006
Adj R2 = 0.257
D-KEFSTM TRAIL MAKING (SCALED SCORE)
1. Number scanning ns ns ns p = 0.013
(Adj R2 = 0.199)
2. Number sequencing ns ns (0.173) p = 0.007
Adj R2 = 0.232
3. Letter sequencing ns (0.089) 0.232 p = 0.002
Adj R2 = 0.276
4. Number-letter sequencingns ns (0.135) p = 0.043
(Adj R2 = 0.137)
5. Motor ns ns ns ns
Motor contrast score ns ns ns ns
FAS WORD ASSOCIATION
Number of words ns ns ns p = 0.006
Adj R2 = 0.234
WASI-II BLOCK DESIGN
Standard score (T-score) ns ns (0.162) p = 0.041
(Adj R2 = 0.140)
Non-adjusted score 0.140 (0.105) 0.225 p = 0.009
(Adj R2 = 0.214)
ECAS
Language ns ns ns ns
Verbal fluency (0.097) ns ns p = 0.006
Adj R2 = 0.232
Executive ns (0.124) (0.126) ns
Memory (0.070) ns ns ns
Visospatial ns ns ns ns
Total score ns ns ns ns
ns, not significant (p > 0.05) before correction for multiple comparisons. Adj R2 values in
brackets were no longer significant after Benjamini-Hochberg correction.
for multiple testing) in the D-KEFS number scanning and motor
trails, as well as the Block Design standard score.
Total VWML also increased with age in DM1-affected subjects
(p < 0.001, Adj R2 = 0.355; Figure 3A). This model did not
improve with inclusion of sex, CTG repeat length (logPAL
or MAL), BMI, or smoking status in a multivariate model.
VWML did not correlate with performance in any of the
neuropsychology assessments measured.
There was a trend toward greater depression and self-
reported cognitive impairment scores in patients with lower
VWML (Figures 3B,C). Higher score in the informant-DEX was
significantly associated with greater VWML (p= 0.001, Adj R2 =
0.278) (Figure 3D).
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TABLE 5 | Standardized beta coefficients and significance of predictor variables in the model Score ∼ age + sex + GMV + DM1-ActivC©.
Age Sex GMV DM1-ActivC© Whole model Adj R2 (p)
STROOP TEST (T-SCORE)
Word task p = 0.023
Beta = 0.521
p = 0.196
Beta = −0.206
p = 0.001
Beta = 0.862
p = 0.074
Beta = 0.272
0.327
(p = 0.002)
Color task p = 0.080
Beta = 0.361
p = 0.100
Beta = −0.244
p < 0.001
Beta = 0.884
p = 0.123
Beta = 0.219
0.425
(p < 0.001)
Color-word task p = 0.048
Beta = 0.461
p = 0.002
Beta = −0.514
p = 0.001
Beta = 0.868
p = 0.903
Beta = 0.018
0.333
(p = 0.002)
Interference p =0.650
Beta = 0.110
p = 0.002
Beta = −0.566
p = 0.050
Beta = 0.517
p = 0.668
Beta = −0.069
0.238
(p = 0.014)
D-KEFSTM TRAIL MAKING (SCALED SCORE)
1. Number scanning p = 0.001
Beta = 0.747
p = 0.849
Beta = −0.028
p = 0.001
Beta = 0.775
p = 0.001
Beta = 0.506
0.410
(p < 0.001)
2. Number sequencing p = 0.040
Beta = 0.497
p = 0.101
Beta = −0.434
p = 0.013
Beta = 0.653
p = 0.089
Beta = 0.267
0.274
(p = 0.005)
3. Letter sequencing p = 0.061
Beta = 0.444
p = 0.015
Beta = −0.405
p = 0.003
Beta = 0.782
p = 0.147
Beta = 0.223
0.300
(p = 0.003)
4. Number-letter sequencing p = 0.269
Beta = 0.286
p = 0.109
Beta = −0.288
p = 0.032
Beta = 0.609
p = 0.364
Beta = 0.154
0.134
(p = 0.064)
5. Motor p = 0.309
Beta = 0.237
p = 0.731
Beta = −0.055
p = 0.461
Beta = 0.182
p < 0.001
Beta = 0.603
0.299
(p = 0.003)
Motor contrast score p = 0.714
Beta = 0.097
p = 0.156
Beta = −0.261
p = 0.074
Beta = 0.514
p = 0.053
Beta = −0.343
0.088
(p = 0.130)
FAS WORD ASSOCIATION
Number of words p = 0.001
Beta = 0.917
p = 0.419
Beta = −0.136
p = 0.004
Beta = 0.805
p = 0.604
Beta = 0.083
0.218
(p = 0.014)
WASI-II BLOCK DESIGN
Standard score (T-score) p = 0.650
Beta = 0.111
p = 0.079
Beta = −0.302
p = 0.162
Beta = 0.370
p = 0.047
Beta = 0.328
0.213
(p = 0.015)
Non-adjusted score p = 0.589
Beta = −0.127
p = 0.099
Beta = −0.271
p = 0.266
Beta = 0.280
p = 0.052
Beta = 0.307
0.277
(p = 0.004)
ECAS
Language p = 0.181
Beta = 0.364
p = 0.094
Beta = 0.316
p = 0.627
Beta = 0.140
p = 0.226
Beta = 0.215
0.048
(p = 0.229)
Verbal fluency p = 0.002
Beta = 0.824
p = 0.559
Beta = 0.098
p = 0.032
Beta = 0.580
p = 0.696
Beta = −0.063
0.213
(p = 0.016)
Executive p = 0.254
Beta = 0.259
p = 0.265
Beta = 0.198
p = 0.074
Beta = 0.500
p = 0.273
Beta = 0.186
0.135
(p = 0.062)
Memory p = 0.203
Beta = −0.352
p = 0.270
Beta = 0.209
p = 0.475
Beta = −0.209
p = 0.300
Beta = 0.187
0.021
(p = 0.328)
Visospatial p = 0.871
Beta = 0.046
p = 0.521
Beta = −0.125
p = 0.335
Beta = 0.292
p = 0.883
Beta = 0.027
0.048
(p = 0.687)
Total score p = 0.146
Beta = 0.386
p = 0.169
Beta = 0.250
p = 0.113
Beta = 0.449
p = 0.294
Beta = 0.181
0.104
(p = 0.102)
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FIGURE 3 | Clinical correlates of total white matter lesion volume (VWML). (A) VWML is increased in DM1-affected subjects compared with controls, and is
age-dependent. (B,C) Demonstrate trends toward higher reporting of depression and cognitive impairment symptoms respectively in patients with lower VMWL. (D)
Demonstrates a positive relationship between VWML and everyday executive dysfunction reported by a proxy (informant-DEX).
DISCUSSION
In this study, a range of CNS outcome measures currently
recommended for use in clinical trials were applied to a
moderate-sized cohort of adults with DM1, and compared
against age-matched controls. Correlations were explored with
CTG repeat length and MRI evidence of global DM1-
related brain changes. The results highlight several important
considerations for CNS outcomemeasure selection in the context
of DM1 clinical trials.
The feasibility of any protocol for DM1 clinical trials must be
considered in the context of the physical limitations, fatigability
and behavioral traits present in such cohorts (38), since these
factors could result in a lower threshold for poor compliance
or withdrawal compared with other groups. Despite this, the
test protocol we describe was not significantly compromised
by disengagement or inability to complete tasks. Furthermore,
the neuropsychology test battery was apparently sensitive to
impairment in DM1, detecting effect sizes of ∼ −0.5 to −1.5
standard deviations compared with controls, with smaller effects
in verbal and memory domains, consistent with the profile
described in DM1 (16). These findings therefore support the
feasibility and sensitivity of the neuropsychology assessments and
self-reported questionnaires described for use in clinical studies.
Specificity of the neuropsychology battery for central vs.
peripheral effects of DM1 was less clear, however. The Stroop
and Trail Making Tests are commonly used in clinical and
research contexts, and are broadly consideredmeasures of higher,
executive cognitive functions (69). The color-word task of the
Stroop requires the subject to suppress a habitual impulse (to
say the written word), and instead perform an unfamiliar task
(saying the color of ink), while the number-letter switching task
of the Trail Making test demands cognitive flexibility to switch
repeatedly between two unrelated sequences. In reality however,
both are complex tasks, and performance depends on additional
domains including attention and basic processing speed (70, 71).
In both tests, comparison with controls showed a similar, large
effect size for a simplified version of the task (the color and
word cards of the Stroop test, and motor task of the Trail
Making Tests) as for the key executive component (the color-
word card and number-letter switching trail). Correction of the
Stroop color-word score for basic reading speed reduced this
large effect size to a moderate Cohen’s d value, closer to that of
the executive subscore of ECAS. In the D-KEFS Trail Making
Tests, correction of the number-letter switching score for basic
motor speed eliminated any significant difference compared to
controls, suggesting that a more basic speed limitation is the
major contributor to poorer performance in the DM1-affected
group.
A speed limitation affecting the simpler conditions of the
Stroop or Trail Making Tests has been observed in some previous
DM1 studies (12, 20, 45, 47). The nature of this limitation
has not been specifically explored, though it has generally been
held to reflect a more global cognitive impairment, or deficit
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in basic processing (72). Slowing of basic processing is a key
feature of cognitive aging in the general population (73), and
has been linked to reduced integrity of white matter and loss of
gray matter volume in older adults (74, 75), including reduced
integrity of fronto-striatal white matter tracts, and volume of
subcortical structures (76). These structural changes are likely
to be accelerated as part of the global brain changes seen in
DM1, hence an exaggeration of the normal decline in basic speed
might be predicted. The fact that we detected a basic speed
limitation affecting both manual and vocal modalities could
be consistent with a central, domain-general cause. A central
slowing of information processing could further be speculated
to underlie features of adynamia or apparent apathy that are
frequently described in in DM1 (77).
On the other hand, some authors have questioned whether
physical limitations due to DM1 might significantly contribute
to the impairment detected by complex cognitive tests such as
the Stroop (78). Recent data have highlighted similar concerns
in studies of cognitive aging, noting that manual dexterity
significantly contributes to performance in traditional paper-
and-pencil assessments of cognitive processing speed in older
adults (79). Interference from peripheral weakness would
undermine use of such tools as CNS outcome measures in DM1
drug trials, since a therapy that successfully improves peripheral
weakness or myotonia, and so increases reading aloud speed
or manual dexterity, could erroneously give the impression of
having impacted cognition. Our data demonstrate significant
correlations of performance in key components of the Stroop,
Trail Making Tests, and Block Design subtest with GMV after
accounting for age and sex, suggesting structural brain changes
are major modifiers of performance. However, inclusion of
DM1-ActivC© score in a multivariate model supports the
hypothesis that muscle impairment accounts for some of the
residual variation in performance in the Stroop Color and Word
tasks, as well as all elements of the Trail Making Tests. Perhaps
unsurprisingly, the effects of muscle were most pronounced
in the number scanning and motor components of the Trail
Making Tests.
The Block Design test is also a common cognitive assessment,
used primarily to assess visuospatial skills (80). Standard scoring
systems are again heavily weighted to reward rapid completion of
the designs, hence we hypothesized that distal muscle weakness
in DM1 might account for a major portion of the deficit detected
compared with controls. In this test however, we observed that
the large effect size persisted despite elimination of weighting
for speed in the non-adjusted score. Further, scores showed
some positive correlation with the visuospatial and executive
subscores of ECAS. These findings suggest the Block Design
test is indeed sensitive for impairment of visuospatial cognition
in DM1 patients. Although the non-adjusted score improved
correlations with ePAL and GMV compared with the standard
score, this should be interpreted with caution since this value
could not be age-adjusted due to a lack of normative data.
Overall, our neuropsychology data suggest that there would
be value in further work to determine the nature of the basic
speed limitation detected in DM1 by the Stroop and Trail
Making Tests, and in particular to distinguish whether this is
related to peripheral muscle impairment or other central factors.
Furthermore, development and validation of assessments that
are not excessively influenced by manual dexterity or dysarthria,
perhaps utilizing assistive technology, would also be a useful step
toward clinical trial readiness.
In self-reported symptom questionnaires, we observed strong
mutual correlations between symptoms of fatigue, pain and low
mood, consistent with the model of inter-relatedness between
mental wellbeing and physical symptoms in DM1 that has
driven recent research into cognitive behavioral therapy-based
interventions (81). Patients with lower mood reported more
somatic symptoms in general, particularly relating to cognition
and social performance. This self-reported impairment was not
generally reflected in poorer performance in neuropsychological
assessments and, similar to the observations of previous authors
(35, 82), we found a trend toward greater reporting of depression
and central symptoms in those with milder white matter change
on MRI. It is unclear whether this trend reflects increasing
acceptance of symptoms over time, or reduced awareness as has
been previously described (51). In contrast, executive symptoms
rated by a relative or carer showed a positive relationship with the
severity of MRI changes. These data therefore suggest that self-
reported symptoms alone are not an effective means to quantify
the severity of the primary disease process in brain in DM1 study
cohorts, and highlight a possible role for proxy measures as part
of a global CNS assessment.
Since study visits for future clinical trials are likely to include
additional effort-intensive measures of muscle symptoms as well
as a CNS assessment protocol, it remains desirable to minimize
redundant or duplicate outcome measures. It is therefore useful
to note that, consistent with previous data (83), subscores within
the MDHI correlated well with other measures of similar themes.
This supports the MDHI as a good stand-alone measure of self-
reported symptoms. This is with the caveat that, as outlined
above, self-reported symptom scales may be influenced by mood
or insight issues, and hence should be supported by objective
measures of the relevant disease process where possible in the
context of a clinical trial.
Correlations of CTG repeat length with neuropsychology
assessments were comparatively poor. Several factors likely
contribute to this observation, including relatively small cohort
size, which may be subject to selection bias, and selection for
adult onset DM1 only (excluding severe phenotypes and thus
large repeat sizes). Because the cognitive phenotype in DM1 is
generally one of mild impairment within the general population
range, (in contrast to muscle weakness, which may be affected
well outwith the range of normal variation), it may be that the
effect of CTG repeat length on themultifactorial trait of cognition
is too subtle to detect within the sample tested. A more marked
effect of repeat length on muscle strength compared with central
phenotypes is supported by the observation that the strongest
genetic correlation observed in our cohort was with the MDHI
mobility score.
With regard to genotype-phenotype correlations, it is also
noteworthy that the three individuals identified with variant
repeats reported particularly mild muscle impairment in DM1-
ActivC ©. This adds to growing evidence that individuals with
DM1 due to variant repeats may be statistical outliers in terms
of disease severity (54), and so reinforces a role for robust
Frontiers in Neurology | www.frontiersin.org 11 October 2018 | Volume 9 | Article 780
Hamilton et al. Outcome Measures in Myotonic Dystrophy
genotyping, including screening for variant repeats, in DM1
clinical trials.
Although this study was not intended primarily to evaluate
MRI biomarkers, it was interesting to note an apparent sex
effect on GMV in this cohort. Inclusion of sex in a multivariate
model improved both correlations of GMV with age, and with
performance in several neuropsychology assessments, although
stringent correction for multiple comparisons meant some could
not be considered significant. To our knowledge, sex-specific
differences in gray matter atrophy have not specifically been
explored in DM1, but in the general population, a marginally
greater rate of gray matter atrophy in males is observed (84).
Therefore, given that several features of DM1 show a sex bias
in penetrance (85), it is plausible that a sex effect on gray
matter atrophy might exist in DM1. This finding highlights sex
as an important cofactor to consider in future studies aiming
to identify imaging biomarkers. Unlike global GMV, VWML
did not correlate well with cognitive impairment measured by
neuropsychology assessments, nor with CTG repeat length in this
study. Given that white matter lesions in the general population
may be influenced by vascular risk factors (86), it is probable that
additional environmental and/or genetic factors also influence
the severity of VWMLs in DM1, which may limit their potential
for use as a disease-specific biomarker. Further studies in larger
cohorts, using a variety of imaging modalities and regional
structural measures as well as a longitudinal design are warranted
to identify clinically meaningful imaging markers in DM1.
CONCLUSIONS
This case control study applied a range of CNS measures with
potential for use in clinical trials to 45 adults with DM1. Our
data highlight muscle impairment and possible deficits in simple
information processing as potential confounders of performance
in complex neuropsychology assessments, particularly Trail
Making and Stroop tests. We demonstrated that low mood is
associated with greater self-reporting of central symptoms in
general, and that significant depression appears to be more
common in those withmilder CNS involvement. An apparent sex
effect was observed in volumetric analysis of global gray matter,
which shows promise as a potential outcome measure, although
further longitudinal studies in a larger population using a range
of MRI modalities are indicated to identify and validate imaging
biomarkers.
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